Both thrombotic and inflammatory mediators contribute to the development of vascular disease. Blood platelets, which are known to play an essential role in ischemic heart disease and stroke by contributing to acute thrombotic events, also release potent inflammatory agents within the vasculature. Lysophosphatidic acid (LPA) is a bioactive lipid mediator that is produced by platelets and found in abundance in human atherosclerotic plaques. LPA stimulates platelets, leukocytes, endothelial cells, and smooth muscle cells by acting through specific cell surface G-protein coupled receptors (LPA1-3) to regulate cell growth, differentiation, survival, motility, and contractile activity. LPA may also be an agonist for the nuclear peroxisome proliferator-activated receptor gamma (PPARgamma). Thus, LPA is poised to serve as a key mediator of both inflammatory and thrombotic responses and to be a pathophysiologic regulator of vascular cell function. The objective of this application is to determine the physiologic contribution of LPA to events that are relevant to atherothrombotic vascular disease and to identify the LPA receptor(s) involved. Our central hypothesis is that LPA generated, in part, by activated platelets stimulates phenotypic modulation of medial SMCs and that these responses regulate vascular tone and contribute to the development of intimal hyperplasia after arterial injury and in the setting of atherosclerosis. We propose to test our hypothesis by integrating cellular, pharmacologic and functional genomics approaches in the following three specific aims (1) establish a pathologic role for LPA in the vascular response to injury; (2) identify LPA receptors that mediate phentypic modulation of cultured vascular SMCs; (3) Identify the role of LPA receptors in the regulation of vascular tone. To accomplish our goals, we will use mice deficient in the three known G-protein coupled LPA receptors (LPA1-3), novel pharmacologic sub-type selective agonists and agonistists of LPA1-3, and mice with a PPARgamma mutation that abolishes ligand binding. Our results will provide specific insights into the role of LPA signaling pathways in vascular physiology and pathology and may provide novels targets for the treatment and prevention of atherothrombotic disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL078663-04
Application #
7281642
Study Section
Special Emphasis Panel (ZHL1-CSR-I (S1))
Program Officer
Goldman, Stephen
Project Start
2004-09-24
Project End
2009-08-31
Budget Start
2007-09-01
Budget End
2009-08-31
Support Year
4
Fiscal Year
2007
Total Cost
$238,941
Indirect Cost
Name
University of Kentucky
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Dong, Anping; Mueller, Paul; Yang, Fanmuyi et al. (2017) Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice. Thromb Res 159:58-64
Mueller, Paul; Ye, Shaojing; Morris, Andrew et al. (2015) Lysophospholipid mediators in the vasculature. Exp Cell Res 333:190-4
Wu, Tao; Kooi, Craig Vander; Shah, Pritom et al. (2014) Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J 28:861-70
Panchatcharam, Manikandan; Salous, Abdel K; Brandon, Jason et al. (2014) Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability. Arterioscler Thromb Vasc Biol 34:837-45
Totani, Licia; Piccoli, Antonio; Dell'Elba, Giuseppe et al. (2014) Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury. Arterioscler Thromb Vasc Biol 34:1689-96
Smyth, Susan S; Mueller, Paul; Yang, Fanmuyi et al. (2014) Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. Arterioscler Thromb Vasc Biol 34:479-86
Nagareddy, Prabhakara; Smyth, Susan S (2013) Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol 20:457-63
Ren, H; Panchatcharam, M; Mueller, P et al. (2013) Lipid phosphate phosphatase (LPP3) and vascular development. Biochim Biophys Acta 1831:126-32
Gross, A Kendall; Dunn, Steven P; Feola, David J et al. (2013) Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 35:147-54
Panchatcharam, Manikandan; Miriyala, Sumitra; Salous, Abdelghaffar et al. (2013) Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler Thromb Vasc Biol 33:52-9

Showing the most recent 10 out of 46 publications